MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on January 29, 2008; DOI: 10.1124/mol.107.040634


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.040634v1
73/5/1465    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fu, Y.
Right arrow Articles by Chen, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fu, Y.
Right arrow Articles by Chen, A.


Received for publication August 8, 2007.
Revised January 28, 2008.
Accepted for publication January 29, 2008.

Epigallocatechin-3-gallate inhibits growth of activated hepatic stellate cells by enhancing the capacity of glutathione synthesis

Yumei Fu 1, Shizhong Zheng 1, Shelly C. Lu 2, Anping Chen 3*

1 St. Louis University 2 University of Southern Californi 3 Saint Louis University

* Address correspondence to: E-mail: achen5{at}slu.edu

Abstract

Activation of hepatic stellate cells (HSC), the key effectors in hepatic fibrogenesis, is characterized by enhanced cell proliferation and overproduction of extracellular matrix (ECM). Oxidative stress promotes HSC activation. Glutathione (GSH) is the most important intracellular antioxidant, whose synthesis is mainly regulated by glutamate-cysteine ligase (GCL). We previously reported that (-)-epigallocatechin-3-gallate (EGCG), the major and most active component in green tea extracts, inhibited HSC activation. The aim of this study is to elucidate the underlying mechanisms. We hypothesize that this inhibitory effect of EGCG might mainly result from its antioxidant capability by increasing de novo synthesis of GSH. In this report, we observe that EGCG enhances the levels of cytoplasmic and mitochondrial GSH and increases GCL activity by inducing gene expression of the catalytic subunit GCLc, leading to de novo synthesis of GSH. Real-time PCR and Western blotting analyses show that de novo synthesis of GSH is required for EGCG to regulate expression of genes relevant to apoptosis and to cell proliferation. Additional experiments demonstrate that exogenous TGF-{beta}1 suppresses GCLc gene expression and reduces the level of GSH in cultured HSC. Transient transfection assays and Western blotting analyses further display that EGCG interrupts TGF-{beta}signaling by reducing gene expression of TGF-{beta} receptors and Smad4, leading to increased expression of GCLc. These results support our hypothesis and collectively demonstrate that EGCG increases the level of cellular GSH in HSC by stimulating gene expression of GCLc, leading to the inhibition of cell proliferation of activated HSC in vitro.


Key words: Regulation of gene expression, Regulation - transcriptional, Glutathione, Oxidative stress/antioxidants, Oxidative stress





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics